Cargando…
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. APPROACH AND RESULTS: Patients with iCCA fro...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252018/ https://www.ncbi.nlm.nih.gov/pubmed/33073396 http://dx.doi.org/10.1002/hep.31598 |
_version_ | 1783717213786603520 |
---|---|
author | Lamarca, Angela Santos‐Laso, Alvaro Utpatel, Kirsten La Casta, Adelaida Stock, Simone Forner, Alejandro Adeva, Jorge Folseraas, Trine Fabris, Luca Macias, Rocio I.R. Krawczyk, Marcin Krawczyk, Marek Cardinale, Vincenzo Braconi, Chiara Alvaro, Domenico Evert, Matthias Banales, Jesus M. Valle, Juan W. |
author_facet | Lamarca, Angela Santos‐Laso, Alvaro Utpatel, Kirsten La Casta, Adelaida Stock, Simone Forner, Alejandro Adeva, Jorge Folseraas, Trine Fabris, Luca Macias, Rocio I.R. Krawczyk, Marcin Krawczyk, Marek Cardinale, Vincenzo Braconi, Chiara Alvaro, Domenico Evert, Matthias Banales, Jesus M. Valle, Juan W. |
author_sort | Lamarca, Angela |
collection | PubMed |
description | BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. APPROACH AND RESULTS: Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS‐CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I‐III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan‐Meier and Cox regression) was performed in an ENS‐CCA training cohort (TC) and findings internally (ENS‐CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS‐CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS‐CCA and SEER registries were reclassified into group C, respectively. In the ENS‐CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18‐5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS‐CCA iVC (HR, 2.93; 95% CI, 2.04‐4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68‐2.09; P < 0.001). CONCLUSIONS: iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including “liver metastases: multiple liver lesions, with or without vascular invasion” as an “M1a stage,” is suggested. |
format | Online Article Text |
id | pubmed-8252018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82520182021-07-07 Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System Lamarca, Angela Santos‐Laso, Alvaro Utpatel, Kirsten La Casta, Adelaida Stock, Simone Forner, Alejandro Adeva, Jorge Folseraas, Trine Fabris, Luca Macias, Rocio I.R. Krawczyk, Marcin Krawczyk, Marek Cardinale, Vincenzo Braconi, Chiara Alvaro, Domenico Evert, Matthias Banales, Jesus M. Valle, Juan W. Hepatology Original Articles BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. APPROACH AND RESULTS: Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS‐CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I‐III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan‐Meier and Cox regression) was performed in an ENS‐CCA training cohort (TC) and findings internally (ENS‐CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS‐CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS‐CCA and SEER registries were reclassified into group C, respectively. In the ENS‐CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18‐5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS‐CCA iVC (HR, 2.93; 95% CI, 2.04‐4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68‐2.09; P < 0.001). CONCLUSIONS: iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including “liver metastases: multiple liver lesions, with or without vascular invasion” as an “M1a stage,” is suggested. John Wiley and Sons Inc. 2021-06-18 2021-06 /pmc/articles/PMC8252018/ /pubmed/33073396 http://dx.doi.org/10.1002/hep.31598 Text en © 2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Lamarca, Angela Santos‐Laso, Alvaro Utpatel, Kirsten La Casta, Adelaida Stock, Simone Forner, Alejandro Adeva, Jorge Folseraas, Trine Fabris, Luca Macias, Rocio I.R. Krawczyk, Marcin Krawczyk, Marek Cardinale, Vincenzo Braconi, Chiara Alvaro, Domenico Evert, Matthias Banales, Jesus M. Valle, Juan W. Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System |
title | Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System |
title_full | Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System |
title_fullStr | Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System |
title_full_unstemmed | Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System |
title_short | Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System |
title_sort | liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252018/ https://www.ncbi.nlm.nih.gov/pubmed/33073396 http://dx.doi.org/10.1002/hep.31598 |
work_keys_str_mv | AT lamarcaangela livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT santoslasoalvaro livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT utpatelkirsten livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT lacastaadelaida livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT stocksimone livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT forneralejandro livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT adevajorge livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT folseraastrine livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT fabrisluca livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT maciasrocioir livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT krawczykmarcin livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT krawczykmarek livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT cardinalevincenzo livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT braconichiara livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT alvarodomenico livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT evertmatthias livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT banalesjesusm livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT vallejuanw livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem AT livermetastasesofintrahepaticcholangiocarcinomaimplicationsforanupdatedstagingsystem |